Cancer Research and Treatment

Volume 39(3); September 2007

Original Articles

The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer: Jae-Sook Ahn, Sang-Hee Cho, Ok-Ki Kim, Joon-Kyoo Lee, Deok-Hwan Yang, Yeo-Kyeoung Kim, Je-Jung Lee, Sang-Chul Lim, Hyeoung-Joon Kim, Woong-Ki Chung, Ik-Joo Chung; Cancer Res Treat. 2007;39(3):93-98. Published online September 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.3.93

Purpose

This study was performed to determine the feasibility and safety of the use of induction chemotherapy combined with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiation therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Materials and Methods

The patients, that were initially not treated for locally advanced SCCHN, underwent three cycles of induction chemotherapy every 3 weeks at a dose of 70 mg/m² docetaxel D1, 75 mg/m² cisplatin D1, 1000 mg/m² 5-FU D1-4, and subsequently received concurrent chemoradiation therapy.

Results

Forty-nine patients were enrolled in this study and forty-three of the patients completed the treatment. The median duration of follow-up was 18 months (range, 6~39 months). All of the patients had stage III (26.5%) or IV (73.5%) squamous cell carcinoma. After sequential therapy, a complete response and partial response was seen in 28 (65.2%) and 13 (30.2%) patients, respectively. The overall response rate was 95.4%. Overall survival and progression-free survival (PFS) at 2 years were 88.7% and 69.7%, respectively. Grade 3~4 neutropenia occurred in 42.2% of the patients and grade 4 thrombocytopenia in 1 cycle (0.7%). Two patients (4.1%) died during the induction chemotherapy due to pneumonia and a subdural hemorrhage, respectively. The group of patients over 65 years of age showed a significant lower dose intensity than that of patients under 65 years of age, but PFS was not significantly different between two groups (p=0.105).

Conclusion

TPF induction chemotherapy followed by concurrent chemoradiotherapy showed a high level of CR and moderate treatment-induced toxicity. Adequate dose modification in elderly patients should be considered to maintain efficacy and avoid treatment-related toxicity.

Citations

Citations to this article as recorded by

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial
Yungan TAO, Xu-Shan Sun, Yoann Pointreau, Christophe Le Tourneau, Christian Sire, Marie-Christine Kaminsky, Alexandre Coutte, Marc Alfonsi, Benôit Calderon, Pierre Boisselier, Laurent Martin, Jessica Miroir, Jean-Francois Ramee, Jean-Pierre Delord, Floria
European Journal of Cancer.2023; 183: 24. CrossRef
Serum Levels of Stromal Cell-Derived Factor-1α and Vascular Endothelial Growth Factor Predict Clinical Outcomes in Head and Neck Squamous Cell Carcinoma Patients Receiving TPF Induction Chemotherapy
Yen-Hao Chen, Chih-Yen Chien, Yu-Ming Wang, Shau-Hsuan Li
Biomedicines.2022; 10(4): 803. CrossRef
Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study
Ching-Yun Hsieh, Ming-Yuh Lein, Shih-Neng Yang, Yao-Ching Wang, Yin-Jun Lin, Chen-Yuan Lin, Chun-Hung Hua, Ming-Hsul Tsai, Ching-Chan Lin
BMC Cancer.2020;[Epub] CrossRef
Neutrophil lymphocyte ratio is an independent prognosticator in patients with locally advanced head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
Hsiang-Lan Lai, Yeh Tang, Chih-Yen Chien, Fu-Min Fang, Tai-Lin Huang, Tai-Jan Chiu, Shau-Hsuan Li
Journal of Cancer Research and Practice.2019; 6(4): 170. CrossRef
Influence of a dosing-time on toxicities induced by docetaxel, cisplatin and 5-fluorouracil in patients with oral squamous cell carcinoma; a cross-over pilot study
Yoshiyuki Tsuchiya, Kentaro Ushijima, Tadahide Noguchi, Naruo Okada, Jun-ichi Hayasaka, Yoshinori Jinbu, Hitoshi Ando, Yoshiyuki Mori, Mikio Kusama, Akio Fujimura
Chronobiology International.2018; 35(2): 289. CrossRef
Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology
D. Alterio, M. Cossu Rocca, W. Russell-Edu, S. Dicuonzo, G. Fanetti, G. Marvaso, L. Preda, S. Zorzi, E. Verri, F. Nole’, B. A. Jereczek-Fossa
Medical Oncology.2017;[Epub] CrossRef
Clinical study on collagen gel droplet-embedded culture drug sensitivity test for multidrug combination chemotherapy and super selective intra-arterial infusion chemoradiotherapy in oral squamous cell carcinoma
Kaname Sakuma, Ryuki Tamura, Shintaro Hanyu, Haruka Takahashi, Hideaki Sato, Takahiro Oneyama, Akira Yamaguchi, Akira Tanaka
Molecular and Clinical Oncology.2017;[Epub] CrossRef
Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
Shau‐Hsuan Li, Wei‐Che Lin, Tai‐Lin Huang, Chang‐Han Chen, Tai‐Jan Chiu, Fu‐Min Fang, Wan‐Ting Huang, Cheng‐Ming Hsu, Sheng‐Dean Luo, Chi‐Chih Lai, Yan‐Ye Su, Hui‐Ching Chuang, Chih‐Yen Chien
Head & Neck.2016;[Epub] CrossRef
Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
Yan-Ye Su, Chih-Yen Chien, Sheng-Dean Luo, Tai-Lin Huang, Wei-Che Lin, Fu-Min Fang, Tai-Jan Chiu, Yen-Hao Chen, Chi-Chih Lai, Cheng-Ming Hsu, Shau-Hsuan Li
World Journal of Surgical Oncology.2016;[Epub] CrossRef
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma
Hironori Cho, Suetaka Nishiike, Yoshifumi Yamamoto, Yukinori Takenaka, Susumu Nakahara, Toshimichi Yasui, Atsushi Hanamoto, Hidenori Inohara
Auris Nasus Larynx.2015; 42(5): 396. CrossRef
Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck
Woo Kyun Bae, Jun Eul Hwang, Hyun Jeong Shim, Sang Hee Cho, Ki Hyeong Lee, Hye Suk Han, Eun-Kee Song, Hwan Jung Yun, In Sung Cho, Joon Kyoo Lee, Sang-Chul Lim, Woong-Ki Chung, Ik-Joo Chung
BMC Cancer.2013;[Epub] CrossRef
Adjuvant Postoperative Radiotherapy with or without Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: The Importance of Patient Selection for the Postoperative Chemoradiotherapy
Jong Hoon Lee, Jin Ho Song, Sang Nam Lee, Jin Hyoung Kang, Min Sik Kim, Dong Il Sun, Yeon-Sil Kim
Cancer Research and Treatment.2013; 45(1): 31. CrossRef
A case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case
Daisuke Iitaka, Atsushi Shiozaki, Hitoshi Fujiwara, Daisuke Ichikawa, Kazuma Okamoto, Shuhei Komatsu, Yasutoshi Murayama, Hisashi Ikoma, Yoshiaki Kuriu, Masayoshi Nakanishi, Toshiya Ochiai, Yukihito Kokuba, Teruhisa Sonoyama, Eigo Otsuji
Surgery Today.2013; 43(5): 556. CrossRef
Usefulness and Indication of Superselective Intra-arterial Chemotherapy via the Radial Artery for Advanced Head and Neck Cancer^|^mdash;a Indication for Inaccessible to Treatment with Seldingers Method^|^mdash;
Junkichi Yokoyama, Shin Ito, Shinichi Ohba, Mitsuhisa Fujimaki, Katsuhisa Ikeda, Makoto Hanaguri
Nippon Jibiinkoka Gakkai Kaiho.2012; 115(6): 625. CrossRef
Examination on the Effect of Docetaxel Dilution Concentration on the Hypersensitivity Revelation Rate
Tatsuya Hayama, Masatoshi Hayasaka, Mei Onuma, Toshimitsu Nakayama, Sadao Amano, Yoshikazu Yoshida
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences).2012; 38(9): 547. CrossRef
Chemotherapy with Modified Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Metastatic Head and Neck Cancer
Jen-Tsun Lin, Guam-Min Lai, Tung-Hao Chang, Mu-Tai Liu, Chu-Ping Bi, Jer-Wei Wang, Mu-Kuan Chen
Advances in Therapy.2012; 29(1): 71. CrossRef
Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue
Minako Suzuki, Hiroshi Ishikawa, Akira Tanaka, Izumi Mataga
Human Cell.2011; 24(1): 21. CrossRef

11,467 View
66 Download
17 Crossref

Oxaliplatin, 5-FU, Folinic Acid as First-line Palliative Chemotherapy in Elderly Patients with Metastatic or Recurrent Gastric Cancer: In Sil Choi, Do-Youn Oh, Byoung-Su Kim, Keun-Wook Lee, Jee Hyun Kim, Jong-Seok Lee; Cancer Res Treat. 2007;39(3):99-103. Published online September 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.3.99

Abstract PDF PubReader ePub

Purpose

We investigated the efficacy and safety of a combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line palliative chemotherapy for elderly patients with metastatic or recurrent gastric cancer.

Materials and Methods

The study patients were chemotherapy-naïve patients (> 65 years old) with histologically confirmed, metastatic or recurrent gastric cancer. Chemotherapy consisted of oxaliplatin 100 mg/m² and FA 100 mg/m² (2-hour infusion), and then 5-FU 2400 mg/m² (46-hour continuous infusion) every 2 weeks.

Results

A total of 37 patients were studied between April 2004 and October 2006. Of the 34 evaluable patients, none achieved a complete response (CR) and 14 achieved a partial response (PR), resulting in an overall response rate of 41.2%. The median time to progression (TTP) was 5.7 months (95% CI: 4.2~6.3 months) and the median overall survival (OS) was 9.8 months (95% CI: 4.4~12.0 months). The main hematologic toxicities were anemia and neutropenia, which were observed in 56.7% and 32.4% of the patients, respectively. Grade 3/4 neutropenia was observed in 8.1% of the patients. None of the patients experienced febrile neutropenia. Peripheral neuropathy occurred in 35.1% of the patients and all were grade 1/2.

Conclusion

This oxaliplatin/5-FU/FA regimen showed good efficacy and an acceptable toxicity profile in elderly patients with metastatic or recurrent gastric cancer.

Citations

Citations to this article as recorded by

Fabrication and evaluation of smart pH/thermo dual-responsive injectable intratumoral in situ depot hydrogels for controlled 5-FU delivery
Samiullah Khan, Bangul Khan, Huan Li
Beni-Suef University Journal of Basic and Applied Sciences.2023;[Epub] CrossRef
Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature
C. de la Fouchardiere, L. Decoster, E. Samalin, C. Terret, C. Kenis, J.P. Droz, C. Coutzac, E. Smyth
Cancer Treatment Reviews.2021; 100: 102289. CrossRef
Fabrication, rheological analysis, and in vitro characterization of in situ chemically cross‐linkable thermogels as controlled and prolonged drug depot for localized and systemic delivery
Samiullah Khan, Naveed Akhtar, Muhammad Usman Minhas
Polymers for Advanced Technologies.2019; 30(3): 755. CrossRef
pH/Thermo-Dual Responsive Tunable In Situ Cross-Linkable Depot Injectable Hydrogels Based on Poly(N-Isopropylacrylamide)/Carboxymethyl Chitosan with Potential of Controlled Localized and Systemic Drug Delivery
Samiullah Khan, Naveed Akhtar, Muhammad Usman Minhas, Syed Faisal Badshah
AAPS PharmSciTech.2019;[Epub] CrossRef
CHEMOTHERAPY IN ELDERLY PATIENTS WITH STOMACH CANCER
O. A. Koroleva, L. M. Kogoniya, M. M. Byakhova, A. G. Titov
Malignant tumours.2018; 8(2): 64. CrossRef
Safety and Efficacy of Dose-dense Chemotherapy with TCF Regimen in Elderly Patients with Locally Advanced or Metastatic Gastric Cancer
Wanda Liguigli, Gianluca Tomasello, Laura Toppo, Rossana Poli, Silvia Lazzarelli, Federica Negri, Bruno Perrucci, Alessandra Curti, Matteo Brighenti, Gianvito Donati, Morena Nazzari, Mario Martinotti, Marco Vismarra, Massimo Rovatti, Rodolfo Passalacqua
Tumori Journal.2017; 103(1): 93. CrossRef
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer
Ji-Won Kim, Keun-Wook Lee, Kyu-Pyo Kim, Ju Hyun Lee, Yong Sang Hong, Jeong-Eun Kim, Sun Young Kim, Sook Ryun Park, Byung-Ho Nam, Sang-Hee Cho, Ik-Joo Chung, Young Suk Park, Ho-Suk Oh, Myung-Ah Lee, Hye Jin Kang, Young Iee Park, Eun-Kee Song, Hye Sook Han,
The Oncologist.2017; 22(3): 293. CrossRef
Facile synthesis of gold nanorods/hydrogels core/shell nanospheres for pH and near-infrared-light induced release of 5-fluorouracil and chemo-photothermal therapy
Hui Jin, Xifeng Liu, Rijun Gui, Zonghua Wang
Colloids and Surfaces B: Biointerfaces.2015; 128: 498. CrossRef
Retracted Article: Facile synthesis of quantum dots/mesoporous silica/quantum dots core/shell/shell hybrid microspheres for ratiometric fluorescence detection of 5-fluorouracil in human serum
Rijun Gui, Ajun Wan, Hui Jin
The Analyst.2013; 138(20): 5956. CrossRef
A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases
Vincenzo Catalano, Renato Bisonni, Francesco Graziano, Paolo Giordani, Paolo Alessandroni, Anna Maria Baldelli, Virginia Casadei, David Rossi, Stefano Luzi Fedeli, Silvia D’Emidio, Lucio Giustini, Giammaria Fiorentini
Gastric Cancer.2013; 16(3): 411. CrossRef
FOLFOX-4 Combination Chemotherapy as a First-line Treatment in Patients with Advanced Gastric Cancer
Cheon Woo Lee, Moo-In Park, Seun Ja Park, Won Moon, Hyung Hun Kim, Hae Won Lee, Ki Hwan Ku, Bu Kyung Kim
Korean Journal of Medicine.2012; 82(1): 37. CrossRef
Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes
In Sil Choi, Hye Seung Lee, Keun-Wook Lee, Haeryoung Kim, Ki Hwan Kim, Yu Jung Kim, Jee Hyun Kim, Woo Ho Kim, Jong Seok Lee
Medical Oncology.2011; 28(4): 991. CrossRef
Biodegradable and thermo-sensitive chitosan-g-poly(N-vinylcaprolactam) nanoparticles as a 5-fluorouracil carrier
N. Sanoj Rejinold, K.P. Chennazhi, S.V. Nair, H. Tamura, R. Jayakumar
Carbohydrate Polymers.2011; 83(2): 776. CrossRef
Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer
Han Jo Kim, Jun Young Eun, Young Woo Jeon, Jina Yun, Kyoung Ha Kim, Se Hyung Kim, Hyun Jung Kim, Sang-Cheol Lee, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Seong-Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park
Cancer Research and Treatment.2011; 43(3): 154. CrossRef
Survival benefit of gastrectomy ± metastasectomy in patients with metastatic gastric cancer receiving chemotherapy
Ki Hwan Kim, Keun-Wook Lee, Sun Kyung Baek, Hye Jung Chang, Yu Jung Kim, Do Joong Park, Jee Hyun Kim, Hyung-Ho Kim, Jong Seok Lee
Gastric Cancer.2011; 14(2): 130. CrossRef
Oxaliplatin and Leucovorin Plus Fluorouracil Versus Irinotecan and Leucovorin Plus Fluorouracil Combination Chemotherapy as a First-line Treatment in Patients with Metastatic or Recurred Gastric Adenocarcinoma
Sun Hyung Kang, Jeong Il Kim, Hee Seok Moon, Seok Hyun Kim, Jae Kyu Sung, Byung Seok Lee, Hyun Yong Jeong
The Korean Journal of Gastroenterology.2010; 55(1): 26. CrossRef
Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer
In Sil Choi, Keun-Wook Lee, Ki Hwan Kim, Yu Jung Kim, Jee Hyun Kim, Jong Seok Lee
Medical Oncology.2010; 27(3): 992. CrossRef
Three-Weekly S-1 Monotherapy as First-Line Treatment in Elderly Patients with Recurrent or Metastatic Gastric Cancer
Joo Han Lim, Moon Hee Lee, Hyung Gil Kim, Yong Woon Shin, Hyeon Gyu Yi, Seok Hwan Shin, Yoon Seok Hur, Chul Soo Kim, Hye Jeong Chang
Gut and Liver.2010; 4(4): 503. CrossRef
Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer
Hye Jin Kim, Keun-wook Lee, Yu Jung Kim, Do-youn Oh, Jee Hyun Kim, Seock-ah Im, Jong Seok Lee
Acta Oncologica.2009; 48(3): 385. CrossRef

10,315 View
82 Download
19 Crossref

Bone Metastasis from Primary Hepatocellular Carcinoma: Characteristics of Soft Tissue Formation: Sangwon Kim, Mison Chun, Heejung Wang, Sungwon Cho, Young-Taek Oh, Seung-Hee Kang, Juno Yang; Cancer Res Treat. 2007;39(3):104-108. Published online September 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.3.104

Abstract PDF PubReader ePub

Purpose

To assess the characteristics of bone metastasis from hepatocellular carcinoma and the radiation field arrangement based on imaging studies.

Materials and Methods

Fifty-three patients (84 lesions) with bone metastasis from a primary hepatocellular carcinoma completed palliative radiation therapy. All patients underwent one of following imaging studies prior to the initiation of radiation therapy: a bone scan, computed tomography or magnetic resonance imaging. The median radiation dose was 30 Gy (7~40 Gy). We evaluated retrospectively the presence of soft tissue formation and the adjustment of the radiation field based on the imaging studies.

Results

Soft tissue formation at the site of bony disease was identified from either a CT/MRI scan (41 lesions) or from a symptomatic palpable mass (5 lesions). The adjustment of the radiation field size based on a bone scan was necessary for 31 of 41 soft tissue forming lesions (75.6%), after a review of the CT/MRI scan. The median survival from the initial indication of a hepatoma diagnosis was 8 months (2 to 71 months), with a 2-year survival rate of 38.6%. The median survival from the detection of a bone metastasis was 5 months (1 to 38 months) and the 1-year overall survival rate was 8.7%.

Conclusion

It was again identified that bone metastasis from a primary hepatocellular carcinoma is accompanied by soft tissue formation. From this finding, an adjustment of the radiation field size based on imaging studies is required. It is advisable to obtain a CT or MRI scan of suspected bone metastasis for better tumor volume coverage prior to the initiation of radiation therapy.

Citations

Citations to this article as recorded by

Hepatocellular carcinoma and musculoskeletal system: A narrative literature review
Jelena Jadzic, Danijela Djonic
World Journal of Gastroenterology.2024; 30(15): 2109. CrossRef
Radiotherapy for bone metastases of hepatocellular carcinoma: a hybrid systematic review with meta-analyses
Chai Hong Rim, Sunmin Park, Won Sup Yoon, In-Soo Shin, Hee Chul Park
International Journal of Radiation Biology.2023; 99(3): 419. CrossRef
Vertebral compression fracture after stereotactic ablative radiotherapy in patients with oligometastatic bone lesions from hepatocellular carcinoma
Tae Hyung Kim, Jina Kim, Joongyo Lee, Taek-Keun Nam, Young Min Choi, Jinsil Seong
Clinical and Translational Radiation Oncology.2023; 41: 100636. CrossRef
Emerging Perspectives of Bone Metastasis in Hepatocellular Carcinoma
Xiaofeng Yuan, Ming Zhuang, Xi Zhu, Dong Cheng, Jie Liu, Donglin Sun, Xubin Qiu, Yunjie Lu, Kurt Sartorius
Frontiers in Oncology.2022;[Epub] CrossRef
Large Oncosome‐Loaded VAPA Promotes Bone‐Tropic Metastasis of Hepatocellular Carcinoma Via Formation of Osteoclastic Pre‐Metastatic Niche
Shuxia Zhang, Xinyi Liao, Suwen Chen, Wanying Qian, Man Li, Yingru Xu, Meisongzhu Yang, Xincheng Li, Shuang Mo, Miaoling Tang, Xingui Wu, Yameng Hu, Ziwen Li, Ruyuan Yu, Ainiwaerjiang Abudourousuli, Libing Song, Jun Li
Advanced Science.2022;[Epub] CrossRef
A case of hepatocellular carcinoma followed by asynchronous metastasis to the lung and thoracic spine following radical ablation treatment
Takafumi Sakuma, Tetsuhiro Chiba, Eiichiro Suzuki, Yoshihiko Ooka, Hiroaki Kanzaki, Kengo Kanayama, Susumu Maruta, Keisuke Koroki, Naoya Kanogawa, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Yuko Kusakabe, Sadahisa
Kanzo.2021; 62(1): 25. CrossRef
Exosomal tumor necrosis factor‐α from hepatocellular cancer cells (Huh‐7) promote osteoclast differentiation
Ching‐Hao Li, Kalaiselvi Palanisamy, Xin Li, Shao‐Hua Yu, I‐Kuan Wang, Chi‐Yuan Li, Kuo‐Ting Sun
Journal of Cellular Biochemistry.2021; 122(11): 1749. CrossRef
Nationwide Patterns of Pathologic Fractures Among Patients Hospitalized With Bone Metastases
Vikram Jairam, Victor Lee, James B. Yu, Henry S. Park
American Journal of Clinical Oncology.2020; 43(10): 720. CrossRef
Hepatocellular Carcinoma with Orbital Metastasis: a Unique Multidisciplinary Case Report
Matthew Michael Sochat, Jinhua Piao, Nishant Poddar
Journal of Gastrointestinal Cancer.2019; 50(4): 978. CrossRef
Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma
Changhoon Choi, Gyu Sang Yoo, Won Kyung Cho, Hee Chul Park
World Journal of Gastroenterology.2019; 25(20): 2416. CrossRef
Atypical magnetic resonance imaging appearance of biopsy-proven spinal metastases in a trauma patient
P Byrapu, S John
Singapore Medical Journal.2019; 60(7): 381. CrossRef
Skeletal metastatic distribution of HCC on 99mTc-MDP bone scan with a unique feature of soft tissue component
Muhammad Iqbal, Muhammad Naeem, Muhammad Imran, Muhammad Afzal, Owais Gill
Pakistan Journal of Nuclear Medicine.2019; : 17. CrossRef
Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoblasts
Alison Shupp, Alexus Kolb, Dimpi Mukhopadhyay, Karen Bussard
Cancers.2018; 10(6): 182. CrossRef
Stereotactic ablative body radiotherapy for spinal metastasis from hepatocellular carcinoma: its oncologic outcomes and risk of vertebral compression fracture
Gyu Sang Yoo, Hee Chul Park, Jeong Il Yu, Do Hoon Lim, Won Kyung Cho, Eonju Lee, Sang Hoon Jung, Youngyih Han, Eun-Sang Kim, Sun-Ho Lee, Whan Eoh, Se-Jun Park, Sung-Soo Chung, Chong-Suh Lee, Joon Hyuk Lee
Oncotarget.2017; 8(42): 72860. CrossRef
High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma
In-Hye Jung, Sang Min Yoon, Jungwon Kwak, Jin-Hong Park, Si Yeol Song, Sang-Wook Lee, Seung Do Ahn, Eun Kyung Choi, Jong Hoon Kim
Oncotarget.2017; 8(9): 15182. CrossRef
Bone Metastases of Hepatocellular Carcinoma: Appearance on MRI Using a Standard Abdominal Protocol
Fernanda Velloni, Miguel Ramalho, Mamdoh AlObaidy, António P. Matos, Ersan Altun, Richard C. Semelka
American Journal of Roentgenology.2016; 206(5): 1003. CrossRef
Cost‐effectiveness of whole‐body bone scans in the pre‐liver transplant assessment of patients with hepatocellular carcinoma in Southern Brazil
Santiago Rodríguez, Giácomo Balbinotto Neto, Guillermo Kiss, Ajacio Brandão
Clinical Transplantation.2016; 30(4): 399. CrossRef
Clinical outcomes of stereotactic body radiotherapy for spinal metastases from hepatocellular carcinoma
Eonju Lee, Tae Gyu Kim, Hee Chul Park, Jeong Il Yu, Do Hoon Lim, Heerim Nam, Hyebin Lee, Joon Hyeok Lee
Radiation Oncology Journal.2015; 33(3): 217. CrossRef
A novel rabbit monoclonal antibody arginase-1 is highly specific and highly sensitive in hepatocellular carcinoma
David E. Tacha, Charlie Yu, Ding Zhou, Thomas Haas
Journal of Histotechnology.2015; 38(4): 128. CrossRef
The many, atypical presentations of musculoskeletal hepatocellular carcinoma (HCC) metastases
Mostafa Mohamed Mostafa Elian, Enas Ahmed Abdel Gawad
The Egyptian Journal of Radiology and Nuclear Medicine.2014; 45(4): 1183. CrossRef
Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey
Daniele Santini, Francesco Pantano, Ferdinando Riccardi, Giovan Giuseppe Di Costanzo, Raffaele Addeo, Francesco Maria Guida, Mariella Spalato Ceruso, Sandro Barni, Paola Bertocchi, Sara Marinelli, Paolo Marchetti, Antonio Russo, Mario Scartozzi, Luca Falo
PLoS ONE.2014; 9(8): e105268. CrossRef
Palliative external-beam radiotherapy for bone metastases from hepatocellular carcinoma
Shinya Hayashi
World Journal of Hepatology.2014; 6(12): 923. CrossRef
Carbon fiber reinforced PEEK Optima—A composite material biomechanical properties and wear/debris characteristics of CF-PEEK composites for orthopedic trauma implants
Ely L. Steinberg, Ehud Rath, Amir Shlaifer, Ofir Chechik, Eran Maman, Moshe Salai
Journal of the Mechanical Behavior of Biomedical Materials.2013; 17: 221. CrossRef
Role of the routine use of chest computed tomography and bone scan in staging workup of hepatocellular carcinoma
Young-Joo Jin, Han Chu Lee, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Kyung-Hyun Do, Jin Sook Ryu
Journal of Hepatology.2012; 56(6): 1324. CrossRef
Multidisciplinary Management of Recurrent Hepatocellular Carcinoma Following Liver Transplantation
Peter J. Kneuertz, David P. Cosgrove, Andrew M. Cameron, Ihab R. Kamel, Jean-Francois H. Geschwind, Joseph M. Herman, Timothy M. Pawlik
Journal of Gastrointestinal Surgery.2012; 16(4): 874. CrossRef
Metastatic Hepatocellular Carcinoma to the Distal Phalanx: a Case Report and Review of Literature
Joo-Hyun Park, Jungkwon Lee, Da-Eun Jung, Soomin Ahn, Kyung-Min Lee, Bo-Kyoung Kim
The Korean Journal of Hospice and Palliative Care.2012; 15(2): 108. CrossRef
Evaluation of Bone Metastasis from Hepatocellular Carcinoma Using 18F-FDG PET/CT and 99mTc-HDP Bone Scintigraphy: Characteristics of Soft Tissue Formation
Hyo Jung Seo, Yun Jung Choi, Hyun Jeong Kim, Yong Hyu Jeong, Arthur Cho, Jae Hoon Lee, Mijin Yun, Hye Jin Choi, Jong Doo Lee, Won Jun Kang
Nuclear Medicine and Molecular Imaging.2011; 45(3): 203. CrossRef
Radiation Therapy for Bone Metastases from Hepatocellular Carcinoma: Effect of Radiation Dose Escalation
Tae Gyu Kim, Hee Chul Park, Do Hoon Lim, Cheol Jin Kim, Hye Bin Lee, Keum Yeon Kwak, Moon Seok Choi, Joon Hyoek Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo
The Journal of the Korean Society for Therapeutic Radiology and Oncology.2011; 29(2): 63. CrossRef

9,437 View
57 Download
28 Crossref

Glucose Transporter-1 Expression in Squamous Cell Carcinoma of the Tongue: Yoon Seok Choi, Seok Jin Kim, Dae Sik Kim, Seh Jong Park, Yong Park, Hye Jin Shin, Kwang-Yoon Jung, Seung-Kuk Baek, Bong Kyung Shin, Jung Woo Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim; Cancer Res Treat. 2007;39(3):109-115. Published online September 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.3.109

Abstract PDF PubReader ePub

Purpose

Tumor cells are known to express hypoxia-related proteins such as glucose transporter-1 (Glut-1). These hypoxia-induced changes may allow tumor cells to survive under sustained hypoxic microenvironments, and the surviving tumor cell under hypoxia may develop a more aggressive phenotype and so result in a poor prognosis.

Materials and Methods

The Glut-1 expression was analyzed by immunohistochemistry, and its association with the prognosis was assessed in 60 patients with squamous cell carcinoma of the tongue.

Results

The Glut-1 expression was diffuse with a membranous pattern, and the median percentage of Glut-1 positive tumor cells was 60% (range: 0.0~90.0%). A high Glut-1 expression (the percentage of positive tumor cells ≥ the median value, 60%) was associated with the location of primary lesion, lymph node metastasis status and disease stage (p<0.05). The expression of Glut-1 was correlated with the Ki-67 expression (r=0.406, p=0.001). Microvessel density, as represented by CD31 staining, was also correlated with the Glut-1 expression although its significance is weak (r=0.267, p=0.039). On the univariate analysis, the group with a high Glut-1 expression showed poorer overall survival than the group with a low Glut-1 expression (p<0.05). However, the Glut-1 expression failed to show any independent prognostic significance on the multivariate analysis.

Conclusion

The expression of Glut-1 may be useful for predicting the prognosis and determining the treatment strategy for the management of squamous cell carcinoma of the tongue.

Citations

Citations to this article as recorded by

Study of expression of GLUT-1 in oral potentially malignant disorders and oral squamous cell carcinoma: An immuno-histochemical analysis
Shylaja K. Attur, Anil Patel, Kailash M. Attur
Journal of Oral and Maxillofacial Pathology.2024; 28(1): 70. CrossRef
Prognostic value of glycolysis markers in head and neck squamous cell carcinoma: a meta-analysis
Yanting Wang, Yuanyuan Li, Laibo Jiang, Xianyue Ren, Bin Cheng, Juan Xia
Aging.2021; 13(5): 7284. CrossRef
The Role of Glucose Transporters in Oral Squamous Cell Carcinoma
Heinrich Botha, Camile S. Farah, Kendrick Koo, Nicola Cirillo, Michael McCullough, Rita Paolini, Antonio Celentano
Biomolecules.2021; 11(8): 1070. CrossRef
Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy
Angara Zambrano, Matías Molt, Elena Uribe, Mónica Salas
International Journal of Molecular Sciences.2019; 20(13): 3374. CrossRef
Can increased metabolic status be a grading tool for oral squamous cell carcinoma? A glucose transporter 1 immunoexpression study
Abikshyeet Panda, Alokenath Bandyopadhyay, Gouse Mohiddin, Malvika Raghuvanshi, SanjayKumar Sahoo, Lipsa Bhuyan
Nigerian Journal of Surgery.2019; 25(2): 203. CrossRef
Plumbagin‐mediating GLUT1 suppresses the growth of human tongue squamous cell carcinoma
S Na, J Zhang, X Zhou, A Tang, D Huang, Q Xu, D Xue, J Qiu
Oral Diseases.2018; 24(6): 920. CrossRef
Expression of GLUT-1 in oral squamous cell carcinoma in tobacco and non-tobacco users
Neha Azad, Malti Kumari Maurya, Meenakshi Kar, Madhu Mati Goel, Ajay Kumar Singh, Mala Sagar, Divya Mehrotra, Vijay Kumar
Journal of Oral Biology and Craniofacial Research.2016; 6(1): 25. CrossRef
Distribution of Hypoxia-Inducible Factor-1α and Glucose Transporter-1 in Human Tongue Cancers
Marcelo Gadelha Vasconcelos, Rodrigo Gadelha Vasconcelos, Denise Hélen Imaculada Pereira de Oliveira, Edilmar de Moura Santos, Leão Pereira Pinto, Éricka Janine Dantas da Silveira, Lélia Maria Guedes Queiroz
Journal of Oral and Maxillofacial Surgery.2015; 73(9): 1753. CrossRef
Expression of glucose transporters in cancers
Leszek Szablewski
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2013; 1835(2): 164. CrossRef
T-Type Ca2+Channels in Normal and Abnormal Brain Functions
Eunji Cheong, Hee-Sup Shin
Physiological Reviews.2013; 93(3): 961. CrossRef
Glucose uptake mediated by glucose transporter 1 is essential for early tooth morphogenesis and size determination of murine molars
Hiroko Ida-Yonemochi, Mitsushiro Nakatomi, Hidemitsu Harada, Hiroki Takata, Otto Baba, Hayato Ohshima
Developmental Biology.2012; 363(1): 52. CrossRef
Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary
Ja Seung Koo, Haeryoung Kim
Tumor Biology.2011; 32(5): 893. CrossRef

10,869 View
57 Download
12 Crossref

Functional Link between DNA Damage Responses and Transcriptional Regulation by ATM in Response to a Histone Deacetylase Inhibitor TSA: Jong-Soo Lee; Cancer Res Treat. 2007;39(3):116-124. Published online September 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.3.116

Abstract PDF PubReader ePub

Purpose

Mutations in the ATM (ataxia-telangiectasia mutated) gene, which encodes a 370 kd protein with a kinase catalytic domain, predisposes people to cancers, and these mutations are also linked to ataxia-telangiectasia (A-T). The histone acetylaion/deacetylation- dependent chromatin remodeling can activate the ATM kinase-mediated DNA damage signal pathway (in an accompanying work, Lee, 2007). This has led us to study whether this modification can impinge on the ATM-mediated DNA damage response via transcriptional modulation in order to understand the function of ATM in the regulation of gene transcription.

Materials and Methods

To identify the genes whose expression is regulated by ATM in response to histone deaceylase (HDAC) inhibition, we performed an analysis of oligonucleotide microarrays with using the appropriate cell lines, isogenic A-T (ATM^-) and control (ATM⁺) cells, following treatment with a HDAC inhibitor TSA.

Results

Treatment with TSA reprograms the differential gene expression profile in response to HDAC inhibition in ATM^- cells and ATM⁺ cells. We analyzed the genes that are regulated by TSA in the ATM-dependent manner, and we classified these genes into different functional categories, including those involved in cell cycle/DNA replication, DNA repair, apoptosis, growth/differentiation, cell- cell adhesion, signal transduction, metabolism and transcription.

Conclusions

We found that while some genes are regulated by TSA without regard to ATM, the patterns of gene regulation are differentially regulated in an ATM-dependent manner. Taken together, these finding indicate that ATM can regulate the transcription of genes that play critical roles in the molecular response to DNA damage, and this response is modulated through an altered HDAC inhibition-mediated gene expression.

Citations

Citations to this article as recorded by

DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment
Takayuki Saitoh, Tsukasa Oda
Cancers.2021; 13(3): 504. CrossRef
p53/E2F1/miR-25 axis regulates apoptosis induction in glioblastoma cells: a qualitative model
Daner A Silveira, Shantanu Gupta, José Carlos M Mombach
Journal of Physics: Complexity.2020; 1(3): 035001. CrossRef
Natural molecules as modulators of epigenetic silencing in human cells for cancer care and aging
Aleksandra Kosianova, Vladlena Tiasto, Margarita Yatsunskaya, Yuri Khotimchenko, Alexander Kagansky
Biological Communications.2020;[Epub] CrossRef
Chromatin Modifications Associated with DNA Double-strand Breaks Repair as Potential Targets for Neurological Diseases
Camille Brochier, Brett Langley
Neurotherapeutics.2013; 10(4): 817. CrossRef
Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling
K. Ted Thurn, Scott Thomas, Paromita Raha, Ian Qureshi, Pamela N. Munster
Molecular Cancer Therapeutics.2013; 12(10): 2078. CrossRef
Characterization of the transcriptome profiles related to globin gene switching during in vitro erythroid maturation
Biaoru Li, Lianghao Ding, Wei Li, Michael D Story, Betty S Pace
BMC Genomics.2012;[Epub] CrossRef
ATM regulates a DNA damage response posttranscriptional RNA operon in lymphocytes
Krystyna Mazan-Mamczarz, Patrick R. Hagner, Yongqing Zhang, Bojie Dai, Elin Lehrmann, Kevin G. Becker, Jack D. Keene, Myriam Gorospe, Zhenqui Liu, Ronald B. Gartenhaus
Blood.2011; 117(8): 2441. CrossRef
Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells
Praveen Rajendran, Emily Ho, David E Williams, Roderick H Dashwood
Clinical Epigenetics.2011;[Epub] CrossRef
ATM modulates transcription in response to histone deacetylase inhibition as part of its DNA damage response
Eun Ryoung Jang, Jae Duk Choi, Mi Ae Park, Gajin Jeong, Hyeseong Cho, Jong-Soo Lee
Experimental and Molecular Medicine.2010; 42(3): 195. CrossRef

9,738 View
67 Download
9 Crossref

Activation of ATM-dependent DNA Damage Signal Pathway by a Histone Deacetylase Inhibitor, Trichostatin A: Jong-Soo Lee; Cancer Res Treat. 2007;39(3):125-130. Published online September 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.3.125

Abstract PDF PubReader ePub

Purpose

Ataxia-telangiectasia mutated (ATM) kinase regulates diverse cellular DNA damage responses, including genome surveillance, cell growth, and gene expression. While the role of histone acetylation/deacetylation in gene expression is well established, little is known as to whether this modification can activate an ATM-dependent signal pathway, and whether this modification can thereby be implicated in an ATM-mediated DNA damage response.

Materials and Methods

Formation of H2AXγ foci was examined in HeLa and U₂OS cells following treatment with a histone deacetylase inhibitor, Trichostatin A (TSA). We determine an ATM-dependency of the TSA-induced DNA damage signal pathway using isogenic A-T (ATM^-) and control (ATM⁺) cells. We monitored the phosphorylation of ATM, an ATM-downstream effector kinase, Chk2, and H2AXγ to detect the activation of the ATM-de pendent DNA damage signal pathway.

Results

Exposure of cells to TSA results in the formation of H2AXγ foci in HeLa and U₂OS cells. The TSA-induced formation of H2AXγ foci occurs in an ATM-dependent manner. TSA induces phosphorylation of serine 1981 of ATM, accumulation of phosphorylated H2AX and Chk2, and formation of H2AX foci, in a manner analogous to genotoxic DNA damage.

Conclusion

In this work, we show that TSA induces a DNA damage signaling pathway in an ATM-dependent manner. These results suggest that ATM can respond to altered histone acetylation induced by the histone deacetylase inhibitor, TSA.

Citations

Citations to this article as recorded by

Prime Editing: Mechanistic Insights and DNA Repair Modulation
Astrid Mentani, Marcello Maresca, Anna Shiriaeva
Cells.2025; 14(4): 277. CrossRef
Making gene editing accessible in resource limited environments: recommendations to guide a first-time user
Shivani Goolab, Janine Scholefield
Frontiers in Genome Editing.2024;[Epub] CrossRef
Increased DNA damage in full-grown oocytes is correlated with diminished autophagy activation
Fei Sun, Nourhan Nashat Ali, Daniela Londoño-Vásquez, Constantine A. Simintiras, Huanyu Qiao, M. Sofia Ortega, Yuksel Agca, Masashi Takahashi, Rocío M. Rivera, Andrew M. Kelleher, Peter Sutovsky, Amanda L. Patterson, Ahmed Z. Balboula
Nature Communications.2024;[Epub] CrossRef
Phosphorylation-mediated disassembly of C-terminal binding protein 2 tetramer impedes epigenetic silencing of pluripotency in mouse embryonic stem cells
Han-Teo Lee, Young Ah Kim, Sangho Lee, Ye-Eun Jung, Hanbyeol Kim, Tae Wan Kim, Sojung Kwak, Jaehyeon Kim, Chul-Hwan Lee, Sun-Shin Cha, Jinmi Choi, Eun-Jung Cho, Hong-Duk Youn
Nucleic Acids Research.2024; 52(22): 13706. CrossRef
Modulating CRISPR/Cas9 genome-editing activity by small molecules
Siwei Chen, Deng Chen, Bin Liu, Hidde J. Haisma
Drug Discovery Today.2022; 27(4): 951. CrossRef
Genetic variations in ATM and H2AX loci contribute to risk of hematological abnormalities in individuals exposed to BTEX chemicals
Samaneh Jafari Roshan, Yaser Mansoori, Seyed Reza Hosseini, Davood Sabour, Abdolreza Daraei
Journal of Clinical Laboratory Analysis.2022;[Epub] CrossRef
TSA Promotes CRISPR/Cas9 Editing Efficiency and Expression of Cell Division-Related Genes from Plant Protoplasts
Seung Hee Choi, Myoung Hui Lee, Da Mon Jin, Su Ji Ju, Woo Seok Ahn, Eun Yee Jie, Ji Min Lee, Jiyoung Lee, Cha Young Kim, Suk Weon Kim
International Journal of Molecular Sciences.2021; 22(15): 7817. CrossRef
Targeting repair pathways with small molecules increases precise genome editing in pluripotent stem cells
Stephan Riesenberg, Tomislav Maricic
Nature Communications.2018;[Epub] CrossRef
CCR6 Is a Predicting Biomarker of Radiosensitivity and Potential Target of Radiosensitization in Rectal Cancer
Hui Chang, Jia-wang Wei, Ya-lan Tao, Pei-rong Ding, Yun-fei Xia, Yuan-hong Gao, Wei-wei Xiao
Cancer Research and Treatment.2018; 50(4): 1203. CrossRef
CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells
M Sauer, M Schuldner, N Hoffmann, A Cetintas, K S Reiners, O Shatnyeva, M Hallek, H P Hansen, S Gasser, E P von Strandmann
Oncogene.2017; 36(7): 933. CrossRef
Myelodysplasia-associated mutations in serine/arginine-rich splicing factor SRSF2 lead to alternative splicing of CDC25C
Lindsey Skrdlant, Jeremy M. Stark, Ren-Jang Lin
BMC Molecular Biology.2016;[Epub] CrossRef
Loss of H3K9me3 Correlates with ATM Activation and Histone H2AX Phosphorylation Deficiencies in Hutchinson-Gilford Progeria Syndrome
Haoyue Zhang, Linlin Sun, Kun Wang, Di Wu, Mason Trappio, Celeste Witting, Kan Cao, Michael Shing-Yan Huen
PLOS ONE.2016; 11(12): e0167454. CrossRef
Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition
Lisa Lange, Peter Hemmerich, Birgit Spänkuch
Oncotarget.2015; 6(28): 25801. CrossRef
A Small-Molecule Probe of the Histone Methyltransferase G9a Induces Cellular Senescence in Pancreatic Adenocarcinoma
Yuan Yuan, Qiu Wang, Joshiawa Paulk, Stefan Kubicek, Melissa M. Kemp, Drew J. Adams, Alykhan F. Shamji, Bridget K. Wagner, Stuart L. Schreiber
ACS Chemical Biology.2012; 7(7): 1152. CrossRef
Development of a High-Content High-Throughput Screening Assay for the Discovery of ATM Signaling Inhibitors
Catherine Bardelle, Joanna Boros
SLAS Discovery.2012; 17(7): 912. CrossRef
The MRN complex in double‐strand break repair and telomere maintenance
Brandon J. Lamarche, Nicole I. Orazio, Matthew D. Weitzman
FEBS Letters.2010; 584(17): 3682. CrossRef
ATM modulates transcription in response to histone deacetylase inhibition as part of its DNA damage response
Eun Ryoung Jang, Jae Duk Choi, Mi Ae Park, Gajin Jeong, Hyeseong Cho, Jong-Soo Lee
Experimental and Molecular Medicine.2010; 42(3): 195. CrossRef
Modulating Polo-Like Kinase 1 as a Means for Cancer Chemoprevention
Travis L. Schmit, Mark C. Ledesma, Nihal Ahmad
Pharmaceutical Research.2010; 27(6): 989. CrossRef

9,731 View
75 Download
18 Crossref

Case Reports

Extraskeletal Mesenchymal Chondrosarcoma of the Heart Responded to Systemic Chemotherapy: A Case Report: Chien Ter Hsing, Sung Yong Oh, Suee Lee, Hyuk-Chan Kwon, Sung-Hyun Kim, Tae-Ho Park, Jong Soo Woo, Seo Hee Na, Hyo-Jin Kim; Cancer Res Treat. 2007;39(3):131-133. Published online September 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.3.131

Abstract PDF PubReader ePub

Mesenchymal chondrosarcoma is a rare cartilaginous ne - oplasm of an extraskeletal origin, and this predominately occurs in the head and neck, and also in the lower extremities. Fewer than twenty cases of cardiac mesenchymal chondrosarcoma have so far been reported on. For the most part, the results of treatment for patients with this condition have been dismal. In this study, we describe a case of cardiac mesenchymal chondrosarcoma that responded to chemotherapy following surgical biopsy. A 46-year-old man was referred for evaluation of his pleural effusions in both lungs. Chest computed tomography revealed an ovoid-shaped mass in the posterior wall of the patient's left atrium. The echocardiogram revealed a large ovoid-shaped immobile mass (11×6 cm²) in the pericardiac space, which was attached to the posterior wall of the left atrium. Emergency pericardiostomy with closure thoracostomy was performed. Seven days later, a thoracotomy was performed for reduction and diagnosis of the cardiac mass. The pathological diagnosis was extraskeletal mesenchymal chondrosarcoma of the heart.. Postoperative chemotherapy was performed for the huge remaining mass with a combined regimen of etoposide, ifosfamide and cisplatin. After 6 cycles, the patient showed a partial response without symptoms. Although cardiac mesenchymal chondrosarcoma has been reported to be chemotherapy-resistant with a short survival duration, chemotherapy may prove to be an effective treatment modality.

Citations

Citations to this article as recorded by

Unusual Presentation of Extraskeletal Mesenchymal Chondrosarcoma: A Case Report
Mathilde Bernard, Ramy Samargandi
Cureus.2023;[Epub] CrossRef
Mesenchymal chondrosarcoma: imaging features and clinical findings
Soleen Ghafoor, Meera R. Hameed, William D. Tap, Sinchun Hwang
Skeletal Radiology.2021; 50(2): 333. CrossRef
18F-FDG PET/CT Findings of Mesenchymal Chondrosarcoma of the Orbit
Mitsuteru Tsuchiya, Takayuki Masui, Yoshiro Otsuki, Harumi Sakahara
Clinical Nuclear Medicine.2018; 43(2): e43. CrossRef
Mesenchymal chondrosarcoma of the orbit: imaging features of CT and MRI
Mitsuteru Tsuchiya, Takayuki Masui, Yoshiro Otsuki, Harumi Sakahara
The British Journal of Radiology.2018; 91(1090): 20170579. CrossRef
Radiofrequency ablation of metastatic chondrosarcoma-associated refractory ventricular tachycardia originating from the right ventricular outflow tract: A case report and literature review
Xiangmin Shi, Zhuo Liang, Jian Li, Jianping Guo, Zhaoliang Shan, Yutang Wang
Experimental and Therapeutic Medicine.2016; 12(3): 1803. CrossRef
A Rare Case of Extraskeletal Mesenchymal Chondrosarcoma with Dedifferentiation Arising from the Buccal Space in a Young Male
Shalini R. Gupta, Ravinder K. Saran, Pankaj Sharma, Aadithya B. Urs
Journal of Maxillofacial and Oral Surgery.2015; 14(S1): 293. CrossRef
Mesenchymal Chondrosarcoma of Bone and Soft Tissue: A Systematic Review of 107 Patients in the Past 20 Years
Jie Xu, Dasen Li, Lu Xie, Shun Tang, Wei Guo, David M Loeb
PLOS ONE.2015; 10(4): e0122216. CrossRef
A fatal case of primary cardiac chondrosarcoma presenting with amaurosis fugax
Jens Sundbøll, Nils Henrik Stubkjær Hansson, Steen Baerentzen, Manan Pareek
BMJ Case Reports.2015; : bcr2015212178. CrossRef
Extraskeletal Intraspinal Mesenchymal Chondrosarcoma; 18F-FDG PET/CT Finding
EunSeong Lee, Ho Young Lee, Gheeyoung Choe, Ki-Jeong Kim, Won Woo Lee, Sang Eun Kim
Clinical Nuclear Medicine.2014; 39(1): e64. CrossRef
Management of renal extraskeletal mesenchymal chondrosarcoma
Vitalie Gherman, Ciprian Tomuleasa, Catalina Bungardean, Nicolae Crisan, Victor-Dan Ona, Bogdan Feciche, Alexandru Irimie, Ioan Coman
BMC Surgery.2014;[Epub] CrossRef
Primary Cardiac Chondrosarcoma
Guofei Zhang, Xiaofan Chen, Lei Guo, Qiang Feng, Yiming Ni
Journal of Cardiac Surgery.2012; 27(2): 186. CrossRef

9,727 View
52 Download
11 Crossref

A Locally Advanced Breast Cancer with Difficult Differential Diagnosis of Carcinosarcoma and Atypical Medullary Carcinoma, which had Poor Response to Adriamycin- and Taxane-based Neoadjuvant Chemotherapy: A Case Report: Se Hyun Kim, Hyun Cheol Chung, Jaeheon Jeong, Ji Hoon Kim, Sun Young Rha, Joong Bae Ahn, Nam Hoon Cho, Hei-Cheul Jeung; Cancer Res Treat. 2007;39(3):134-137. Published online September 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.3.134

Abstract PDF PubReader ePub

Atypical medullary carcinomas and carcinosarcoma have unique histopathological features. Here we present a case with a breast malignancy that had pathological characteristics of both. A 54-year old patient with a malignant breast mass received 6 cycles of adriamycin-based chemotherapy, followed by 3 cycles of paclitaxel monotherapy, and had a poor clinical response to treatment. A modified radical mastectomy was performed. The pathological diagnosis was complicated by an inability to distinguish between atypical medullary carcinoma and carcinosarcoma. The findings included a tumor that was well-circumscribed, high grade and a syncytial growth pattern as well as biphasic sarcomatous and carcinomatous characteristics. In conclusion, atypical medullary carcinoma and carcinosarcoma of the breast have entirely different prognoses and should be managed differently. Both should be treated by surgical resection, and additional therapy should be considered based on the cancer with the poorer prognosis.

Citations

Citations to this article as recorded by

Carcinosarcoma of the breast: Facing the challenge of a rare nosologic entity
Aikaterini Mastoraki, Maria Tsamopoulou, Foivos-Konstantinos Stamatis, Alexios Strimpakos, Ero Mouchtouri, Christiana Panagi, Evgenia Mela, Sotiria Mastoraki, Aristotelis Kechagias, Dimitrios Schizas
World Journal of Clinical Cases.2025;[Epub] CrossRef
A Rare Case of Primary Carcinosarcoma of the Breast
Maria Kiakou, Maria Tolia, Nektarios Koufopoulos, Konstantinos Tsapakidis, Eleni Arvanitou, Gkikas Konstantinos, Nikolaos Charalambakis, Michalis Nikolaou, Dimitrios Matthaios, Nikolaos Tsoukalas
Forum of Clinical Oncology.2022; 13(1): 48. CrossRef
Carcinosarcoma (Metaplastic Carcinoma) Breast: A Rare and Aggressive Primary – Report of Two Cases with Review of Literature
Gunjesh Kumar Singh, Pragya Singh, KT Bhowmik
Indian Journal of Medical and Paediatric Oncology.2018; 39(03): 400. CrossRef
Carcinosarcoma of the Breast: An Aggressive Subtype of Metaplastic Cancer. Report of a Rare Case in a Young BRCA-1 Mutated Woman
Matteo Ghilli, Donatella M. Mariniello, Giovanni Fanelli, Francesca Cascione, Andrea Fontana, Agostino Cristaudo, Anna Cilotti, Adelaide M. Caligo, Giampiero Manca, Livio Colizzi, Antonio G. Naccarato, Manuela Roncella
Clinical Breast Cancer.2017; 17(1): e31. CrossRef

9,814 View
70 Download
4 Crossref

First
Prev
Page of 1
Next
Last

Previous issues